Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, Phase 1 study to evaluate the impact of hepatic
impairment on the pharmacokinetics of Tivantinib in cancer subjects with varying degrees of
hepatic function, from normal to severely impaired.